Clinical Trial

QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy

Name: QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy — clinical trial record (NCT07141186)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To explore the efficacy and safety of administrating QL1706 in patients with recurrent and/or metastatic cervical cancer who had developed resistance to prior PD-1/PD-L1 antibody therapies.

Trial Details

NCT Number	NCT07141186
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital
Conditions	Cervical Cancer, Cervical Cancer Metastatic, Cervical Cancer Recurrent, Cervical Adenocarcinoma, Cervical Cancer Squamous Cell
Enrollment	50 participants
Start Date	2025-10-01
Primary Completion	2027-10-01 (estimated)
Study Completion	2030-10-01 (estimated)
Updated on ClinicalTrials.gov	2025-08-26